Naslov
Colchicine in Patients with Chronic Coronary Disease

Autori
Lucijanić, Marko ; Javor, Eugen ; Skelin, Marko

Izvornik
The New England journal of medicine (0028-4793) 384 (2021), 8; 777-778

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
Colchicine ; Chronic Coronary Disease

Sažetak
In the LoDoCo2 trial, patients with chronic coronary disease who received colchicine had a lower risk of cardiovascular events than those who received placebo but did not have a corresponding lower risk of death. Clonal hematopoiesis of indeterminate potential (CHIP ; the presence of leukemia-associated gene mutations in patients without detectable hematologic cancer) increases in incidence with age, and clones that consist of at least 10% of circulating nucleated cells are found in 10 to 15% of adults who are older than 70 years of age.1 CHIP is associated with increased cardiovascular morbidity and mortality owing to accelerated atherosclerosis caused by proinflammatory interactions between endothelium and clonal monocytes (mediated by the NLRP3 inflammasome).

Izvorni jezik
Engleski

POVEZANOST RADA